SCHEMBL29566982

SCHEMBL29566982

Cc1cccc(C)c1-c1cc(Oc2ccc(C(=O)O)c(Cl)c2)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 2/20 0.38
▸ SLC6A9 P48067 2/20 0.37
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ AVPR2 P30518 1/20 0.35
▸ GPR27 Q9NS67 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ EGFR P00533 2/20 0.34
▸ FGFR1 P11362 2/20 0.34
▸ KDR P35968 2/20 0.34
▸ PCTP Q9UKL6 1/20 0.34
▸ STARD10 Q9Y365 1/20 0.34
▸ GPR119 Q8TDV5 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310549 1.00 ACLY (0.38) ACLYSLC6A9CYP2C9CYP2C19AVPR2
SCHEMBL26810187 0.92 SLC6A9 (0.38) SLC6A9AVPR2GPR27EGFRFGFR1
SCHEMBL26810192 0.90 GPR119 (0.40) SLC6A9AVPR2GPR27EGFRFGFR1
SCHEMBL26810190 0.89 SLC6A9 (0.40) SLC6A9AVPR2GPR27EGFRFGFR1
SCHEMBL29566957 0.89 SLC6A9 (0.39) SLC6A9AVPR2GPR27PCTPSTARD10
SCHEMBL24310786 0.89 SLC6A9 (0.39) SLC6A9AVPR2GPR27PCTPSTARD10
SCHEMBL29566838 0.88 GFER (0.39) TSHRSMN1; SMN2EGFRFGFR1KDR
SCHEMBL24310039 0.88 GFER (0.39) TSHRSMN1; SMN2EGFRFGFR1KDR
SCHEMBL26810218 0.86 KMT2A (0.40) TSHRSMN1; SMN2EGFRFGFR1KDR
SCHEMBL24310791 0.86 EGFR (0.38) ACLYTSHRSMN1; SMN2EGFRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback